5682-75-7Relevant academic research and scientific papers
C-O Bond Activation as a Strategy in Palladium-Catalyzed Cross-Coupling
Becica, Joseph,Leitch, David C.
, p. 641 - 646 (2020/12/14)
The activation of strong C-O bonds in cross-coupling catalysis can open up new oxygenate-based feedstocks and building blocks for complex-molecule synthesis. Although Ni catalysis has been the major focus for cross-coupling of carboxylate-based electrophiles, we recently demonstrated that palladium catalyzes not only difficult C-O oxidative additions but also Suzuki-Type cross-couplings of alkenyl carboxylates under mild conditions. We propose that, depending on the reaction conditions, either a typical Pd(0)/(II) mechanism or a redox-neutral Pd(II)-only mechanism can operate. In the latter pathway, C-C bond formation occurs through carbopalladation of the alkene, and C-O cleavage by β-carboxyl elimination. 1 Introduction 2 A Mechanistic Challenge: Activating Strong C-O Bonds 3 Exploiting Vinylogy for C-Cl and C-O Oxidative Additions 4 An Alternative Mechanism for Efficient Cross-Coupling Catalysis 5 Conclusions and Outlook.
Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
Zhang, Hefeng,Peng, Xia,Dai, Yang,Shao, Jingwei,Ji, Yinchun,Sun, Yiming,Liu, Bo,Cheng, Xu,Ai, Jing,Duan, Wenhu
supporting information, p. 3956 - 3975 (2021/04/12)
The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.
PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE
-
Paragraph 01117, (2021/04/02)
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.
QUINOLINE DERIVATIVE
-
Paragraph 0178, (2017/11/17)
This compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity. Consequently, this compound can be a therapeutic agent for Axl-related diseases, for example, cancers such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma, kidney diseases, immune system diseases and cardiovascular diseases.
Copper-Catalyzed Double Additions and Radical Cyclization Cascades in the Re-Engineering of the Antibacterial Pleuromutilin
Ruscoe, Rebecca E.,Fazakerley, Neal J.,Huang, Huanming,Flitsch, Sabine,Procter, David J.
supporting information, p. 116 - 119 (2016/01/26)
A general synthetic sequence involving simply prepared starting materials provides rapid access to diverse, novel tricyclic architectures inspired by pleuromutilin. SmII-mediated radical cyclization cascades of dialdehydes, prepared using a new
Experimental studies on the selective β-c-h halogenation of enones
Huber, Tatjana,Kaiser, Daniel,Rickmeier, Jens,Magauer, Thomas
, p. 2281 - 2294 (2015/03/18)
Here we describe the realization of a one-pot protocol for the β-C-H halogenation of cyclic enones via umpolung of the β-carbon. The developed method includes hydrazone formation and selective β-halogenation (bromination, chlorination) with N-bromosuccini
Cyclization of cyanoethylated ketones as a route to 6-substituted indole derivatives
Bergman, Jan,Stensland, Birgitta
, p. 1 - 10 (2014/02/14)
δ-Cyanoketones are quickly cyclized with KOtBu to 3-aminocyclohex-2-enone derivatives, which in turn will give substituted indoles when treated with oxalyl chloride. Thus, 3-amino-6,6-dimethylcyclohex-2-enone gave 3-chloro-6,6-dimethyl-2,5,6,7-tetrahydroindole-2,5-dione, whose structure was corroborated by X-ray crystallography, whereas the corresponding molecule without the blocking gem-dimethyl groups, 3-aminocyclohex-2-enone, gave via hydrogen shifts 6-chloro-3-hydroxyoxindole.
NOVEL CYP17 INHIBITORS/ANTIANDROGENS
-
Page/Page column 35; 36, (2015/01/07)
Compounds of formula (I), wherein R1 to R8 A, B, Z1 and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17a-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
Cyclization of 5-hexynoic acid to 3-alkoxy-2-cyclohexenones
Hylden, Anne T.,Uzelac, Eric J.,Ostojic, Zeljko,Wu, Ting-Ting,Sacry, Keely L.,Sacry, Krista L.,Xi, Lin,Jones, T. Nicholas
scheme or table, p. 1323 - 1326 (2011/11/06)
The one-pot cyclization of 5-hexynoic acid to produce 3-alkoxy-2- cyclohexenones proceeds in good yields (58-90%). 3-Hexynoic acid was converted to its acyl chloride with the aid of oxalyl chloride and was cyclized to 3-chloro-2-cyclohexenone upon addition of indium(III) chloride. Subsequent addition of alcohol nucleophiles led to the desired 3-alkoxy-2-cyclohexenones.
PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS
-
Page/Page column 72-73, (2011/02/24)
Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.
